Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Acta oncologica (Stockholm, Sweden) 2018 May 1-6.
Brøndum Line, Alsner Jan, Sørensen Brita Singers, Maare Christian, Johansen Jørgen, Primdahl Hanne, Evensen Jan Folkvard, Kristensen Claus Andrup, Andersen Lisbeth Juhler, Overgaard Jens, Eriksen Jesper Gr
- Page last reviewed:Mar 1, 2018
- Page last updated:Jul 11, 2019
- Content source: